AVTR

As of 2026-10-26, AVTR scores 58out of 100 on QNTM’s five-factor quantitative model, a moderate conviction reading. The score blends momentum, quality, volume, value and sentiment, then adjusts for the current macro regime. AVTR trades at $17.29, within its fair-value band.

AVTR scores 58 out of 100 on QNTM's five-factor model — a moderate reading — neither strongly favored nor flagged for weakness at 58. Its strongest factor is momentum at 87 (exceptional), where price trend and relative strength are working in its favor, followed by value at 71. The weakest is quality at 30, where earnings-quality metrics lag. Among Healthcare stocks it ranks in roughly the top 17% of the Healthcare names the model scores.

On valuation, AVTR is priced in the upper part of its recent range. The profile is lopsided — a few factors carry it while others drag, so the composite masks real disagreement underneath. The blended composite before the macro overlay was 59. Same-sector names the model rates nearby include HALO, VEEV, THC.

This is a descriptive factor read on AVTR, recomputed each trading day and shown with its reasoning — not a recommendation to buy, hold or sell. The score reflects where AVTR sits on the model's measures today, and can change as new data arrives.

FACTOR BREAKDOWN

VALUATION RANGE

QNTM’s descriptive fair-value band for AVTR runs $12.71–$20.01. Current price $17.29 sits within its fair-value band. This is valuation context, not a price target.

OTHER HEALTHCARE NAMES

QNTM provides quantitative model outputs for informational and educational purposes only. It is not investment advice and QNTM is not a registered investment adviser. Scores are rankings, not buy/sell recommendations. Data as of 2026-10-26.